… Single agent maintenance therapy is widely accepted for advanced non-squamous non
small cell lung cancer (NSCLC). However, there is no consensus on the initial and maintenance …

… This article presents a summary of the ERG report for the STA of erlotinib as monotherapy
for the maintenance treatment of patients with non-small cell lung cancer (NSCLC) and stable …

… Data from the erlotinib phase 3 trials, TRIBUTE and TALENT, suggested that erlotinib therapy
may be effective as maintenance monotherapy after platinum-based chemotherapy.27, 28 …

… commonly diagnosed cancers and is the leading cause of cancer-… cancer deaths in 2008
were attributable to lung cancer.[1,2] Most cases of lung cancer are non-small-cell lung cancer (…

… To our knowledge, PIN is the first placebo-controlled switch maintenance study of olaparib
in patients relapsed non-small cell lung cancer. Olaparib was associated with both longer …

… pemetrexed plus cisplatin followed by maintenance gefitinib (PC/G) and gefitinib monotherapy
(G) in patients with advanced nonsquamous non–small cell lung cancer (NSCLC) and …

Importance Few clinical trials have been specifically designed for elderly patients with
advanced non–small cell lung cancer (NSCLC), and the anticipated increase in the number of …

… selected lung cancer patients. The primary objective of this study was to assess the PFS of
pemetrexed-cisplatin (PC) followed by gefitinib maintenance versus gefitinib monotherapy in …

… pemetrexed plus cisplatin followed by maintenance gefitinib (PC/G) and gefitinib monotherapy
(G) in patients with advanced nonsquamous non–small-cell lung cancer (NSCLC) and …

… lung cancer (NSCLC), maintenance chemotherapy has been used in the treatment of other
cancers, … maintenance monotherapy had an ICER of $326,530 per quality-adjusted life-year. …